A phase II trial of the effect of perindopril on hand–foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC

PURPOSE: Regorafenib is an oral multi-kinase inhibitor that offers an OS benefit to patients with mCRC refractory to standard therapy (Grothey et al., in Lancet 381:303–312, 2013), but comes with potential significant toxicities including grade 3 hand–foot skin reaction (HFSR). The pathogenesis of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Melosky, Barbara L., Lim, Howard John, Davies, Janine Marie, Gill, Sharlene, Kollmannsberger, Christian K., Ho, Maria Yi, Vandt, Solomon A., Renouf, Daniel John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394486/
https://www.ncbi.nlm.nih.gov/pubmed/30535909
http://dx.doi.org/10.1007/s00280-018-3738-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394486/
https://www.ncbi.nlm.nih.gov/pubmed/30535909
http://dx.doi.org/10.1007/s00280-018-3738-x

Ejemplares similares